文献速递妇科

抑制S1PR2对上皮性卵巢癌SKOV3细胞体内外增殖的影响

[Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2018-01-01

研究设计S1PR2小干扰RNA及S1PR2抑制剂JTE-013,在体外SKOV3细胞和裸鼠腹腔移植瘤模型中观察抑制S1PR2对卵巢癌细胞增殖的影响及机制。结果显示抑制S1PR2可降低SKOV3细胞增殖、提高G0/G1期比例、下调p-ERK1/2,并减少裸鼠移植瘤数目和重量。

要点

  • si-S1PR2转染组S1PR2蛋白表达为0.24±0.04,低于空白对照组1.10±0.14和阴性对照组1.07±0.13(P均<0.01)。
  • 转染24、48、72 h后si-S1PR2组增殖抑制率分别为26.6±3.3%、35.0±3.4%、34.0±2.8%,均高于两对照组(P均<0.01)。
  • JTE-013组裸鼠移植瘤数为8.2±3.7个、瘤重0.21±0.07 g,均少于对照组15.4±4.3个、0.45±0.12 g(P均<0.01)。

核心结论

  • 在体内、外抑制S1PR2蛋白表达后均能降低卵巢癌SKOV3细胞的增殖能力。
  • 其机制之一可能是通过下调ERK1/2通路的磷酸化水平,阻止卵巢癌细胞从G1期到S期的转化。

研究设计与样本

  • 体外实验:以卵巢癌细胞系SKOV3为对象,分为si-S1PR2转染组、阴性对照组和空白对照组,采用蛋白印迹法检测S1PR2蛋白,CCK-8法检测增殖抑制率,流式细胞仪检测细胞周期,蛋白印迹法检测p-ERK1/2。
  • 体内实验:将SKOV3细胞接种于裸鼠腹腔构建腹腔移植瘤模型,分为S1PR2抑制剂组和对照组,每组8只裸鼠,接种后7 d开始分别腹腔给予JTE-013和PBS,每周2次共8次,28 d后处死解剖。

主要发现

  • si-S1PR2转染组S1PR2蛋白相对表达量为0.24±0.04,低于空白对照组1.10±0.14和阴性对照组1.07±0.13(P均<0.01)。
  • 转染24、48、72 h后,si-S1PR2组增殖抑制率分别为26.6±3.3%、35.0±3.4%、34.0±2.8%,高于阴性对照组1.7±0.9%、2.5±0.5%、2.4±1.1%及空白对照组均为0(P均<0.01)。
  • 转染48 h后si-S1PR2组G0/G1期比例为70.9±2.8%,高于空白对照组61.7±2.4%和阴性对照组62.1±3.3%(P均<0.01)。
  • 转染48 h后si-S1PR2组p-ERK1/2相对表达量为0.11±0.03,低于阴性对照组0.68±0.09和空白对照组0.62±0.09(P均<0.01)。
  • JTE-013组裸鼠移植瘤数为8.2±3.7个、瘤重为0.21±0.07 g,分别少于对照组15.4±4.3个、0.45±0.12 g(P均<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To study the effect and mechanism of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo. Methods: (1) A pair of S1PR2 gene small interference RNA (siRNA) , namely si-S1PR2, and a pair of negative control siRNA were designed. Western blot methods were used to detect the silence efficiency of the S1PR2 in the si-S1PR2 group, blank control group and negative control group. (2) Study in vitro: the experiment included three groups, namely si-S1PR2 group, blank control group and negative control group. Cell counting kit-8 (CCK-8) assay was used to detect the proliferation inhibition rates of the transfected cells. The cell cycles of the transfected cells were measured by flow cytometry. Western blot was used to detect the levels of phosph-extracellular regulated protein kinase 1/2 (p-ERK1/2) of the transfected cells. (3) Study in vivo:to establish intraperitoneal transplantation models, 8 mice in each group were intraperitoneally injected with 5×10(6) SKOV3 cells. Phosphate buffered saline (PBS) or JTE-013 were administered into mice twice per week starting on day 7 after the injection of the cancer cells. Twenty-eight days after nude mice intraperitoneal injection with JTE-013 or PBS, the mice were sacrificed and the number and the weight of visible tumors were calculated. Results: (1) The results of western blot showed that the relative S1PR2 protein expression levels were 0.24±0.04 in the si-S1PR2 group, which was lower than that in the blank control group (1.10±0.14, P<0.01) and negative control group (1.07±0.13, P<0.01) . (2) The results of CCK-8 assay indicated that after transfected for 24, 48 and 72 hours, the proliferation inhibition rate of si-S1PR2 group were respectively (26.6±3.3) %, (35.0±3.4) %, and (34.0±2.8) %, significantly lower than those in the blank control group (all 0; all P<0.01) and negative control group [ (1.7±0.9) %, (2.5±0.5) %,and (2.4±1.1) % respectively; all P<0.01]. The results of flow cytometry showed that the G(0)/G(1) ratio in the si-S1PR2 group [ (70.9±2.8) %] was significantly higher than those in the blank control group [ (61.7±2.4) %, P<0.01] and negative control group [ (62.1±3.3) %, P<0.01]. Western blot showed that the relative expression level of p-ERK1/2 in si-S1PR2 group (0.11±0.03) was significantly lower than those in the blank control group [ (0.62±0.09) , P<0.01] and negative control group [ (0.68±0.09) , P<0.01]. (3)Twenty-eight days after nude mice intraperitoneal injection with JTE-013 or PBS, the tumor number of the control group and JTE-013 group were respectively 15.4±4.3 and 8.2±3.7, the tumor weight were (0.45±0.12) and (0.21±0.07) g, respectively. The tumor number and weight in the JTE-013 group were significantly less than those in the control group (all P<0.01) . Conclusions: The growth of ovarian cancer cells could be decreased by S1PR2 inhibition in vitro and in vivo. One of the mechanisms of the growth inhibitory effect is probably that S1PR2 inhibition lower the phosphorylation level of extracellular regulated protein kinase 1/2 (ERK1/2) pathway, which prevent the transformation of ovarian cancer cells from phase G(1) to S. 目的:探讨抑制1-磷酸鞘氨醇受体2(S1PR2)对卵巢上皮性癌(卵巢癌)细胞增殖能力的影响及其作用机制。 方法: (1)设计针对S1PR2基因的小分子干扰RNA(siRNA,命名为si-S1PR2),以及与S1PR2基因无关的siRNA(作为阴性对照);以卵巢癌细胞系SKOV3细胞作为研究对象,实验分为3组,分别为si-S1PR2转染组、阴性对照组和空白对照组,采用蛋白印迹(western blot)法检测3组SKOV3细胞中S1PR2蛋白的表达。(2)体外实验:分组同前,采用活细胞计数(CCK-8)法检测转染后不同时间点(分别为24、48、72 h)3组SKOV3细胞增殖的抑制率;流式细胞仪检测转染后3组SKOV3细胞的细胞周期比例;western blot法检测转染后3组SKOV3细胞中磷酸化细胞外调节蛋白激酶1/2(p-ERK1/2)蛋白的表达水平。(3)体内实验:将SKOV3细胞接种于裸鼠腹腔,构建卵巢癌裸鼠腹腔移植瘤模型。实验分为两组,分别为S1PR2抑制剂组和对照组(每组8只裸鼠),两组裸鼠在腹腔接种SKOV3细胞后7 d开始腹腔给药,分别给予S1PR2抑制剂——JTE-013和磷酸盐缓冲液(PBS),每周2次共8次。28 d后处死并解剖两组裸鼠,观察腹腔移植瘤的生长情况。 结果: (1)western blot法检测显示,si-S1PR2转染组SKOV3细胞中S1PR2蛋白的表达水平为0.24±0.04,与阴性对照组(1.07±0.13)、空白对照组(1.10±0.14)分别比较,差异均有统计学意义(P均<0.01)。(2)CCK-8法检测显示,转染24、48、72 h后,si-S1PR2转染组SKOV3细胞增殖的抑制率[分别为(26.6±3.3)%、(35.0±3.4)%、(34.0±2.8)%]明显高于阴性对照组[分别为(1.7±0.9)%、(2.5±0.5)%、(2.4±1.1)%;P均<0.01]及空白对照组(均为0;P均<0.01)。流式细胞仪检测显示,转染48 h后,si-S1PR2转染组细胞的G(0)/G(1)期比例为(70.9±2.8)%,明显高于空白对照组及阴性对照组[分别为(61.7±2.4)%、(62.1±3.3)%;P均<0.01]。western blot法检测显示,转染48 h后,si-S1PR2转染组细胞中p-ERK1/2蛋白的表达水平为0.11±0.03,明显低于阴性对照组和空白对照组(分别为0.68±0.09、0.62±0.09;P均<0.01)。(3)28 d后处死并解剖裸鼠,S1PR2抑制剂组、对照组裸鼠腹腔内的移植瘤数分别为(8.2±3.7)、(15.4±4.3)个,移植瘤质量分别为(0.21±0.07)、(0.45±0.12)g,两组分别比较,差异均有统计学意义(P均<0.01)。 结论:在体内、外抑制S1PR2蛋白表达后均能降低卵巢癌SKOV3细胞的增殖能力,其机制之一可能是通过下调细胞外调节蛋白激酶1/2(ERK1/2)通路的磷酸化水平,阻止卵巢癌细胞从G(1)期到S期的转化。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dai L, Liu YX, Xie L, et al. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo]. Zhonghua Fu Chan Ke Za Zhi. 2018. PMID: 29534379. doi:10.3760/cma.j.issn.0529-567X.2018.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。